# Computational Strategy for Epitope Mapping of Glycoconjugate Vaccines Using Deep Learning  
## Agent Schools Framework + Virtual Lab Research System

---

## 1. Overview

This document specifies a **full research strategy** for:

> **“Computational Strategy for Epitope Mapping of Glycoconjugate Vaccines using Deep Learning”**

implemented via:

- **Agent Schools** – a structured program to train, specialize, and certify AI research agents in narrow scientific domains.
- **Virtual Lab** – a multi-agent orchestration layer (inspired by Swanson et al., “The Virtual Lab”) where a PI agent leads domain-specialist agents through team meetings and individual meetings to carry out actual research.[web:19][web:22][web:25]

The output is an end-to-end, **reproducible workflow** that generates predicted B‑cell epitopes for glycoconjugate vaccines, along with deep-learning models, structural analyses, and experimental recommendations.

---

## 2. Research Problem Definition

### 2.1 Scientific Background

Glycoconjugate vaccines couple polysaccharides or oligosaccharides to carrier proteins to elicit robust T‑cell–dependent immune responses against bacterial pathogens (e.g., *Neisseria meningitidis*, *Streptococcus pneumoniae*). Epitope mapping in this context is challenging because:

- **Glycans are structurally complex** (branching, linkages, conformational flexibility).
- **Immune recognition depends on both glycan and protein epitopes**, including glycan–protein interfaces.
- **B‑cell epitopes are often conformational**, distributed across non-contiguous regions in sequence but spatially contiguous in 3D.
- Structural data for **full glycoconjugate constructs** (glycans + carrier protein) are sparse.

### 2.2 Core Research Questions

1. Given a glycoconjugate vaccine construct (glycan structure(s) + carrier protein sequence), which **surface regions** constitute **likely B‑cell epitopes**?
2. How do **glycan structures and their conformations** modulate:
   - Epitope accessibility?
   - Immune dominance?
   - Potential cross-reactivity?
3. Can **deep learning models** trained on protein/glycoprotein data learn to:
   - Predict epitope vs. non-epitope regions?
   - Provide interpretable feature attributions (e.g., key residues, glycans, structural motifs)?
4. How can these predictions drive **rational vaccine optimization**, e.g.:
   - Choosing glycan motifs
   - Adjusting conjugation sites
   - Modifying carrier proteins

### 2.3 Constraints and Requirements

- The system must be **tool-integrated**:
  - Structural prediction models (e.g., AlphaFold-like, glycan-aware workflows)
  - Molecular modeling (GLYCAM, Rosetta or equivalents)
  - Protein language models (e.g., ESM family) and structural GNNs
  - Epitope databases (e.g., IEDB) for training and benchmarking[web:19][web:22]
- Decisions must be **traceable**:
  - Agents must justify choices with citations and explicit reasoning.
- The solution must be **modular**, so components can be updated as tools improve.

---

## 3. Agent Schools Framework

### 3.1 Rationale

General-purpose LLMs are breadth-optimized but depth-limited for **niche biochemical and immunological questions**, especially around glycans, conjugation chemistry, and epitope prediction. The Agent Schools framework addresses this by:

- Training **distinct agents** with **specialized curricula**.
- Forcing **explicit study, integration, and testing** before deployment.
- Using a **Teacher/Scientific Critic** to enforce rigor and catch shallow understanding.

### 3.2 Agent Types and Roles

Each agent is defined as in Virtual Lab: **title, expertise, goal, role**.[web:22][web:25]

#### 3.2.1 PI Agent (Principal Investigator)

- **Title**: PI for Computational Glycoconjugate Vaccine Design
- **Expertise**:
  - Interdisciplinary computational biology
  - AI for scientific discovery
  - Vaccine development lifecycle
- **Goal**: Maximize scientific impact and coherence of the research project.
- **Role**:
  - Define project scope and priorities
  - Design meeting agendas and workflows
  - Synthesize agent contributions into decisions

#### 3.2.2 Glyco‑Immunologist Agent

- **Title**: Glyco‑Immunologist
- **Expertise**:
  - B‑cell epitope biology
  - Glycan immunology
  - Vaccine immunogenicity and tolerance
- **Goal**: Provide immunological grounding for epitope predictions and vaccine design.
- **Role**:
  - Interpret predicted epitopes biologically
  - Prioritize epitopes for probable immunogenicity
  - Design immunological validation experiments

#### 3.2.3 Computational Chemist Agent

- **Title**: Computational Structural Chemist
- **Expertise**:
  - Protein/glycoprotein structure prediction
  - Glycan modeling (GLYCAM or similar)
  - Docking and scoring (Rosetta or equivalents)
- **Goal**: Provide structurally realistic models and quantitative interaction scores.
- **Role**:
  - Build 3D models of glycoconjugates
  - Evaluate epitope accessibility and stability
  - Score candidate epitopes via structural metrics

#### 3.2.4 Machine Learning Specialist Agent

- **Title**: ML Specialist for Epitope Prediction
- **Expertise**:
  - Protein language models
  - Geometric/graph deep learning for 3D structures
  - Model interpretability and uncertainty estimation
- **Goal**: Design, train, and interpret epitope prediction models.
- **Role**:
  - Architect deep networks (sequence-only, sequence+structure)
  - Train and evaluate models on epitope datasets
  - Provide feature attributions and model diagnostics

#### 3.2.5 Bioinformatician Agent

- **Title**: Structural Bioinformatician
- **Expertise**:
  - Database mining (PDB, IEDB, UniProt, glycan DBs)
  - Sequence analysis and multiple sequence alignment
  - Serotype and strain variation mapping
- **Goal**: Provide clean data, labels, and comparative analyses.
- **Role**:
  - Pull and preprocess datasets for ML models
  - Map predictions onto known epitope landscapes
  - Evaluate conservation and coverage across strains

#### 3.2.6 Scientific Critic / Teacher Agent

- **Title**: Scientific Critic and Teacher
- **Expertise**:
  - Scientific method
  - Experimental design and statistics
  - Common pitfalls in computational biology
- **Goal**: Maintain rigor; detect errors and weak reasoning.
- **Role**:
  - Critique meeting outputs and code
  - Generate quizzes and tests from corpora
  - Gate graduation from Agent School

---

## 4. Agent School Phases (Training Science Agents)

### 4.1 Phase 1 – Curriculum Development (Weeks 1–3)

#### 4.1.1 Process

1. **Problem Decomposition (PI + Human)**  
   - Identify domain knowledge slices:
     - Glyco-immunology
     - Structural glycoprotein modeling
     - Deep learning for structural biology
     - Structural bioinformatics and sequence analysis
   - Define depth: foundational vs. implementation-level vs. research-frontier.

2. **Curriculum Drafts (Per Agent)**  
   - For each agent:
     - Foundational level: textbooks, reviews (e.g., Essentials of Glycobiology)
     - Intermediate: method papers (e.g., AlphaFold, Rosetta, ESM, IEDB usage)
     - Advanced: cutting-edge primary literature in that subfield.

3. **Assessment Rubric Design**  
   - For each agent:
     - Conceptual understanding criteria
     - Tool proficiency criteria
     - Application/problem-solving criteria

#### 4.1.2 Example: Glyco‑Immunologist Curriculum Skeleton

- **Week 1 – Foundations**
  - B‑cell epitope biology
  - Glycan–immune interactions
  - Glycoconjugate vaccine design basics

- **Week 2 – Epitope Mapping & Glycoconjugates**
  - Experimental epitope mapping methods
  - Known epitope patterns in major glycoconjugate vaccines
  - Influence of carrier proteins and linkers

- **Week 3 – Computational Epitope Prediction**
  - IEDB tools and databases
  - Structure-based epitope prediction methods
  - Integration of computational and experimental approaches

Similar detailed curricula are built for the Computational Chemist, ML Specialist, and Bioinformatician.

---

## 5. Phase 2 – Autonomous Study (Weeks 4–9)

### 5.1 Literature Search & Retrieval

Each student agent:

- Uses domain-appropriate search queries (PubMed, arXiv, etc.).
- Downloads PDFs and supplementary materials.
- Logs all sources into a per-agent bibliography.

Example queries:

- Glyco‑Immunologist:
  - “glycoconjugate vaccine B-cell epitope”
  - “glycan immunogenicity carrier protein”
  - “conjugate vaccine epitope mapping”
- Computational Chemist:
  - “AlphaFold glycoprotein structure prediction”
  - “GLYCAM carbohydrate MD”
  - “Rosetta antibody-antigen interface scoring”
- ML Specialist:
  - “protein language model epitope prediction”
  - “geometric deep learning conformational epitope”

### 5.2 Knowledge Extraction

For each paper:

- Extract:
  - Methods
  - Key results
  - Tools used
  - Validation approaches
  - Limitations
- Build:
  - Concept maps (e.g., linking “N‑linked glycosylation” → “epitope masking” → “accessibility”)
  - Annotated notes highlighting what is relevant for epitope mapping.

### 5.3 Internal Representation

Agents:

- Formulate **mini-reviews** summarizing themes.
- Draft **SOP-style documents** (e.g., “How to use IEDB to create an epitope dataset”).
- Link concepts across papers (e.g., glycan shielding in viral vaccines vs. bacterial glycoconjugates).

---

## 6. Phase 3 – Knowledge Integration & Training (Weeks 10–15)

### 6.1 Retrieval-Augmented Generation (RAG)

For each agent:

- Build a **vector database** of the curated corpus (papers, manuals, tool docs).
- Implement a retrieval layer:
  - For each question, retrieve k most relevant documents.
  - Provide them as context to the underlying LLM.

This ensures the agent can **cite** and reason over actual domain sources, mitigating hallucinations on niche topics.

### 6.2 Optional Fine-Tuning

Where feasible:

- Construct training pairs from literature, e.g.:

  - Instruction: “Explain how GLYCAM parameterizes common bacterial polysaccharides.”
  - Input: Extracted paragraphs from GLYCAM docs/papers.
  - Output: Expert-level explanation.

- Fine-tune a domain-specific model or adapt prompts.

### 6.3 Tool Proficiency

Each agent practices running its domain tools on **toy examples**:

- Computational Chemist:
  - Run glycoprotein predictions (or approximations) using available workflows.
  - Run short MD simulations with glycan force fields.
  - Use structural analysis scripts (contact maps, SASA, distance-based epitopes).

- ML Specialist:
  - Generate ESM embeddings for small proteins.
  - Train a simple classifier on a small epitope dataset.
  - Implement basic attention/feature attribution analysis.

- Bioinformatician:
  - Query IEDB for known epitopes for a chosen pathogen.
  - Map epitopes onto sequences and align serotypes.
  - Generate sequence conservation plots.

---

## 7. Phase 4 – Testing & Certification (Weeks 16–18)

### 7.1 Assessment Format

For each agent:

- **Written exam** (LLM-graded with rubric, plus human spot checks):
  - Conceptual questions
  - Short-answer design questions
- **Practical tasks**:
  - For Chemist: “Given this sequence and glycan info, design a small pipeline to model the structure and identify accessible regions.”
  - For ML Specialist: “Design an architecture for conformational B-cell epitope prediction with interpretability.”

### 7.2 Scoring

Composite score from:

- Conceptual understanding (≈30–40%)
- Tool proficiency (≈30–40%)
- Applied problem-solving (≈20–30%)

Agents with overall **≥80%** are marked **CERTIFIED** for Virtual Lab participation. Others get remedial curricula and re-testing.

---

## 8. Virtual Lab Architecture (Post-School)

The Virtual Lab layer follows the structure described by Swanson et al.:

- Agents defined via prompts specifying **title, expertise, goal, and role**.
- Research organized via **team meetings** and **individual meetings** with multiple rounds and Critic feedback.[web:19][web:22][web:25]

### 8.1 Meeting Types

#### 8.1.1 Team Meetings

- Participants:
  - PI
  - Specialist agents (Glyco‑Immunologist, Chemist, ML, Bioinformatician)
  - Scientific Critic
- Inputs:
  - Agenda
  - Agenda questions
  - (Optional) previous meeting summaries
  - (Optional) external contexts (papers, data)
- Flow:
  - PI opens with context + questions.
  - Each agent responds in sequence.
  - Critic provides critique after each round.
  - PI synthesizes and outputs final recommendations.

#### 8.1.2 Individual Meetings

- One agent + optional Critic.
- Used for:
  - Code implementation
  - Detailed protocol design
  - Focused analyses
- Multiple rounds:
  - Agent proposes → Critic critiques → Agent refines.

---

## 9. Virtual Lab Epitope Mapping Workflow

### 9.1 Phase 1 – Research Planning (Week 20)

**Team Meeting 1: Scope and Targets**

- Agenda:
  - Select specific glycoconjugate vaccines or archetypes (e.g., pneumococcal conjugate).
  - Decide if we focus on a single serotype or multiple serotypes.
  - Define initial **validation metrics** (e.g., ability to recover known epitopes from IEDB).

- Questions:
  - What is the clinical or scientific motivation for choosing these constructs?
  - What prior data exist for epitopes on these antigens?
  - What structural data are available?

**Individual Meeting 1: Data Audit (Bioinformatician)**

- Outputs:
  - List of:
    - Sequences of carrier proteins and glycan motifs.
    - Known epitopes from IEDB (if any).
    - PDB structures or close homologs.
  - Gaps that require modeling.

### 9.2 Phase 2 – Tool and Pipeline Design (Week 21)

**Team Meeting 2: Pipeline Architecture**

- Objectives:
  - Select tools and define pipeline modules:
    - Structure prediction for glycoproteins / conjugates.
    - Glycan conformational sampling.
    - Feature extraction (sequence/structure).
    - ML epitope prediction model(s).
    - Scoring and ranking scheme.
  - Decide integration patterns (sequential vs. parallel branches).

- Example design decisions:
  - Use an AlphaFold-like backbone for protein carriers, combined with glycan modeling via GLYCAM or related tools.
  - Extract:
    - Sequence embeddings via ESM or similar models.
    - Structural features via GNNs (nodes = residues, edges = distances/contacts).
  - For training labels:
    - Use IEDB B-cell epitopes for relevant antigens as training/benchmark data.
    - Consider transfer learning from general epitope datasets to specific glycoconjugates.

- Deliverable:
  - Pipeline diagram with modules:
    1. **Input**: sequence(s), glycan description(s)
    2. Structure modeling
    3. Feature engineering
    4. Model inference
    5. Post-hoc interpretation + ranking
    6. Benchmarking vs. known epitopes

### 9.3 Phase 3 – Module Implementation (Weeks 22–27)

Modules are implemented in **parallel** via individual meetings.

#### 9.3.1 Structure & Glycan Modeling (Computational Chemist)

- Tasks:
  - Implement workflows to:
    - Predict 3D structure of carrier protein.
    - Attach glycan motifs at specified sites.
    - Sample glycan conformations and/or local flexibility.
  - Output:
    - Ensembles of 3D structures.
    - For each structure: per-residue solvent exposure, distances, etc.

#### 9.3.2 Feature Extraction (ML Specialist + Chemist)

- Tasks:
  - Sequence features:
    - ESM/other transformer embeddings per residue.
    - One-hot or biochemical descriptors as backup.
  - Structural features:
    - 3D coordinates and pairwise distances.
    - Surface accessibility, curvature, local environment.
  - Glycan-aware features:
    - Whether a residue is glycosylated or near a glycan.
    - Contact frequency with glycan in simulations.

#### 9.3.3 Dataset & Labeling (Bioinformatician)

- Tasks:
  - Build training/benchmark sets:
    - Retrieve antigens similar to chosen carriers from IEDB.
    - Label residues as epitope vs. non-epitope where possible.
  - Handle class imbalance:
    - Many more non-epitope than epitope residues.
    - Consider focal loss, oversampling, or negative subsampling.

#### 9.3.4 Model Development (ML Specialist)

- Tasks:
  - Model architecture examples:
    - **Sequence-only**: transformer-based epitope classifier using ESM embeddings.
    - **Sequence+structure**: GNN or equivariant model combining embeddings with 3D geometry.
  - Training:
    - Cross-validation on training epitopes.
    - Evaluation on held-out antigens/serotypes.
  - Output:
    - Trained models with performance metrics.
    - Tools for inference on new glycoconjugate constructs.

---

## 10. Phase 4 – Workflow Integration (Week 28)

**Individual Meeting (PI + optionally Critic)**

- Tasks:
  - Define the **canonical workflow** for a new glycoconjugate:
    1. Read sequence and glycan data.
    2. Generate structural ensemble.
    3. Extract features.
    4. Run epitope prediction model(s).
    5. Aggregate predictions across ensemble.
    6. Rank epitopes and generate reports.
  - Define:
    - Thresholds (e.g., probability cutoffs).
    - How to combine sequence-based vs. structure-based predictions.
    - Logging and reproducibility requirements.

- Outputs:
  - Workflow spec document.
  - Implementation plan for orchestrating modules (e.g., using Python workflows, Snakemake, or Nextflow).

---

## 11. Phase 5 – Validation & Interpretation (Weeks 29–31)

**Team Meeting: Results Review**

- Inputs:
  - Ranked epitope list(s) for chosen glycoconjugate(s).
  - Benchmark results vs. known epitopes.
  - Structural visualizations of top-ranked epitopes.

- Glyco‑Immunologist:
  - Evaluates biological plausibility.
  - Considers glycan exposure, immune dominance, tolerance risks.

- Chemist:
  - Checks structural sanity and accessibility.
  - Evaluates stability and potential for cross-reactivity.

- ML Specialist:
  - Explains model confidence and features driving predictions.
  - Flags predictions with low calibration or high uncertainty.

- Bioinformatician:
  - Compares predictions to known epitope databases.
  - Evaluates conservation across serotypes.

- Critic:
  - Challenges assumptions.
  - Points out possible overfitting and biases.
  - Suggests additional benchmarks.

- Output:
  - Final prioritized list of epitopes.
  - Explanation of ranking criteria.
  - Experimental validation plan.

---

## 12. Experimental Validation Plan

While wet-lab execution is outside the AI system, the Virtual Lab should propose:

- **Constructs**:
  - Peptides or glycopeptides representing predicted epitopes.
  - Modified constructs with improved predicted immunogenicity.

- **Assays**:
  - Binding assays (ELISA, BLI, SPR) with:
    - Known monoclonal antibodies, if available.
    - Polyclonal sera from vaccinated animals/subjects.
  - Epitope mapping assays (alanine scanning, competition ELISA).

- **Prioritization**:
  - High-confidence epitopes with multiple supporting signals.
  - Epitopes in conserved regions with cross-serotype potential.

---

## 13. Success Metrics and Evaluation

### 13.1 Agent School Metrics

- Certification rate ≥85%
- Tool proficiency ≥90%:
  - Agents should independently design and run small analyses.
- Interdisciplinary performance:
  - Evaluated qualitatively by Critic during team meetings.

### 13.2 Virtual Lab Metrics

- **Predictive accuracy** vs. known epitopes:
  - Sensitivity (TPR) and specificity (TNR).
  - ROC‑AUC and PR‑AUC.
- **Generalization**:
  - Performance on antigens/serotypes not seen during training.
- **Effort and efficiency**:
  - Human time spent vs. quality of outputs.
  - Number of iterations needed to reach stable pipeline.

### 13.3 Experimental Metrics

- Fraction of synthesized epitopes with validated binding:
  - Target ≥60% as meaningful improvement over random or naive methods.
- Ability to discover **novel** epitopes not in existing databases but validated experimentally.

---

## 14. Infrastructure and Resources

- **Compute**:
  - GPUs for structure modeling and deep learning.
  - CPU resources for data prep and orchestration.
- **Software**:
  - Structural modeling tools (AlphaFold-like, GLYCAM, Rosetta or equivalents).
  - ML frameworks (PyTorch/TensorFlow).
  - RAG stack (vector DB + retrieval library).
- **Data**:
  - IEDB epitope datasets.
  - PDB structural data.
  - Glycan structure databases where available.

---

## 15. Adaptability and Extensions

The same Agent School + Virtual Lab pattern can be applied to:

- Other vaccine targets (viral glycoproteins, protein subunit vaccines).
- Antibody design (swapping in antibody-focused agents and tools).
- ADC linker/target design (with medicinal chemist agents, PK/PD agents).

Minimal changes:

- Agent curricula
- Specific tools (e.g., different MD engines, docking tools)
- Validation criteria

---

## 16. Summary

This strategy operationalizes a **multi-agent AI research lab** tailored to a difficult, niche problem: epitope mapping for glycoconjugate vaccines. It systematically:

1. Trains agents to deep domain competence via Agent Schools.
2. Coordinates them via a Virtual Lab with principled meeting protocols.[web:19][web:22][web:25]
3. Produces a structurally and biologically grounded epitope prediction workflow.
4. Outputs testable hypotheses and software artifacts that can accelerate vaccine design.

Once instantiated, the same infrastructure can be reused and extended across multiple projects and therapeutic targets.

---

*End of `epitope_mapping_research_strategy.md`*
